Article Text
Abstract
A 57-year-old man developed worsening early morning headaches, muscle cramps and falls over 12 months. He had widespread fasciculation and was diagnosed with motor neurone disease, and treated with nocturnal hypoventilation. Based on this diagnosis, he made significant personal and financial decisions including retiring and selling his house. He subsequently developed a lump in his right breast and was found to have gynaecomastia. This triggered genetic testing for Kennedy’s disease leading to the correct diagnosis. This case highlights an unusual presentation of a rare disease leading to misdiagnosis and major repercussions for the patient. Recent genetic analysis from the 100 000 genome project suggests Kennedy’s disease may be four times more prevalent in the population than previously thought, highlighting the need to consider genetic testing, especially if there is a suggestion of multisystem disease.
- MOTOR NEURON DISEASE
- NEUROGENETICS
- GENETICS
- CLINICAL NEUROLOGY
Data availability statement
No data are available.
Statistics from Altmetric.com
Data availability statement
No data are available.
Footnotes
X @HelenDevine10
Contributors HD, MS and DJ prepared the original manuscript. All authors contributed to the article and approved the final version.
Funding HD was supported by an MRC Clinical Research Training Fellowship for this work. PF is supported by a UK MRC Senior Clinical Fellowship and Lady Edith Wolfson Fellowship (MR/M008606/1 and MR/S006508/1), the Neurological Research Trust and KDUK. CR is supported by a Career Development Fellowship grant from the Wellcome Trust to CR (205162/Z/16/Z). MGH is part of the ICGNMD Consortium, funded by an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1.
Competing interests None declared.
Provenance and peer review Not commissioned; Externally peer reviewed by Andrew Chancellor, Tauranga, New Zealand.
Read the full text or download the PDF:
Other content recommended for you
- The profile of motor unit number estimation (MUNE) in spinal and bulbar muscular atrophy
- Split hand and motor axonal hyperexcitability in spinal and bulbar muscular atrophy
- Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA)
- Beyond motor neurons: expanding the clinical spectrum in Kennedy’s disease
- Plasma pNfH levels differentiate SBMA from ALS
- Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy
- Wide range of reduced penetrance alleles in spinal and bulbar muscular atrophy: a model-based approach
- Differentiating lower motor neuron syndromes
- Management of motor neurone disease
- Study protocol for the MEXiletine hydrochloride administration trial: a placebo-controlled, randomised, double-blind, multicentre, crossover study of its efficacy and safety in spinal and bulbar muscular atrophy (MEXPRESS)